|
||
Independent, up-to-date news and information for the multiple myeloma community. |
|
Maintenance therapy with thalidomide (Thalomid) improves progression-free survival of multiple myeloma patients but has no impact on overall survival, according to a recent study. Additionally, patients with an aggressive form of myeloma show no benefit from this treatment. The findings were presented by Dr. James Child of the United Kingdom’s Clinical Trials Research Unit at the European Hematology Association (EHA) annual meeting in Barcelona on June 13.
Maintenance therapy is long-term, often low-dose and continuous, treatment given to prevent …
Preliminary results from two ongoing clinical trials suggest that elotuzumab in combination with either Velcade (bortezomib) or Revlimid (lenalidomide) plus low-dose dexamethasone (Decadron) is effective and well-tolerated in patients who have relapsed or are resistant (refractory) to previous myeloma treatment. The findings were presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago.
Elotuzumab is a new drug being developed by Facet Biotech and Bristol-Myers Squibb as a potential treatment for …
Revlimid (lenalidomide) is an effective maintenance therapy after stem cell transplantation in multiple myeloma patients, according to two Phase 3 studies presented on Sunday at the annual meeting of the American Society of Clinical Oncology (ASCO).
Based on the results of these two studies as well as a previous study, Revlimid maintenance therapy is likely to become a common addition to the treatment of myeloma.
Dr. Sergio Giralt of the MD Anderson Cancer Center in Houston led …
The 46th annual meeting of the American Society of Clinical Oncology (ASCO) kicks off on June 4 in Chicago.
More than 30,000 clinical specialists from all over the world are expected to attend the five day meeting to discuss the most current research in cancer treatment and care. This year’s meeting, which will feature more than 4,000 presentations and posters, will primarily focus on the theme of “Advancing Quality through Innovation.”
The ASCO meeting will include many presentations and seminars …
Leading myeloma specialists from across Europe recently published an article in the journal The Oncologist that summarized the current treatment options and availability of therapeutic agents for multiple myeloma patients in Europe. This article, Part 4 in the series, summarizes the European authors’ recommendations for the management of side effects.
The European authors provided recommendations for managing side effects related to novel agent use in myeloma patients. The recommendations are similar to how the side effects are managed …
A recent study found the combination therapy of thalidomide (Thalomid) and dexamethasone (Decadron), commonly referred to as TD, to be safe and effective as induction therapy in newly diagnosed multiple myeloma patients with impaired kidney function. The study authors also found that 55 percent of participants achieved normal kidney function after TD treatment. The study results were published in the journal Biology of Blood and Marrow Transplantation.
Impaired kidney function is a serious complication that occurs in approximately …
Leading myeloma specialists from across Europe recently published an article in the journal The Oncologist that summarized the current treatment options and availability of therapeutic agents for multiple myeloma patients in Europe. This article, Part 3 in a series, summarizes the European physicians’ treatment recommendations for patients with relapsed myeloma. Part 1 compares availability of myeloma treatments in Europe and the U.S., and part 2 summarizes physician’s treatment recommendations for newly diagnosed patients. Part 4 will cover the …
